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Abstract
Objective: Individuals with epilepsy have poor bone development and preservation 
throughout the lifespan and are vulnerable to nontrauma fracture (NTFx) and post-
NTFx complications. However, no studies have examined the contribution of NTFx 
to mortality among adults with epilepsy. The objective was to determine whether 
NTFx is a risk factor for mortality among adults with epilepsy.
Methods: Data from 2011 to 2016 were obtained from Optum Clinformatics Data 
Mart, a nationwide claims database from a single private payer in the United States. 
Diagnosis codes were used to identify adults (≥18 years old) with epilepsy, NTFx, 
and covariates (demographics and pre-NTFx cardiovascular disease, respiratory 
disease, diabetes, chronic kidney disease, cancer). Crude mortality rate per 100 
person-years was estimated. Cox regression estimated hazard ratios (HRs) and 
95% confidence intervals (CIs) were determined for mortality, comparing epilepsy 
and NTFx (EP + NTFx; n = 11 471), epilepsy without NTFx (EP without NTFx; 
n = 50 384), without epilepsy and with NTFx (without EP + NTFx; n = 423 041), 
and without epilepsy and without NTFx (without EP without NTFx; n = 6.8 million) 
after adjusting for covariates.
Results: The 3-, 6-, and 12-month crude mortality rates were highest among 
EP + NTFx (12-month mortality rate = 8.79), followed by without EP + NTFx (12-
month mortality rate = 4.80), EP without NTFx (12-month mortality rate = 3.06), 
and without EP without NTFx (12-month mortality rate = 0.47). After adjustments, 
the mortality rate was elevated for EP + NTFx for all time points compared to EP 
without NTFx (eg, 12-month HR = 1.70, 95% CI = 1.58-1.85), without EP + NTFx 
(eg, 12-month HR = 1.41, 95% CI = 1.32-1.51), and without EP without NTFx (eg, 
12-month HR = 5.23, 95% CI = 4.88-5.60). Stratified analyses showed higher ad-
justed HRs of 12-month mortality for EP + NTFx for all NTFx sites (ie, vertebral 
column, hip, extremities), all age categories (young, middle-aged, older), and for 
both women and men.
Significance: Among adults with epilepsy and compared to adults without epilepsy, 
NTFx is associated with a higher 12-month mortality rate. Findings suggest that 
NTFx may be a robust risk factor for mortality among adults with epilepsy.
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1 |  INTRODUCTION
Individuals with epilepsy typically require long-term treat-
ment with antiseizure medications to prevent seizures. 
Seizures and antiseizure medications are well established fac-
tors for inadequate skeletal development in children,1 leading 
to low bone mineral density and elevated fracture rate among 
children with epilepsy, in comparison to children without 
epilepsy.2,3 Three to four of five adults with epilepsy have 
skeletal fragility (eg, low bone mineral density),4,5 and frac-
ture risk is considerably elevated among adults with epilepsy 
compared to the general population (relative risk = 1.7-6.2).6
Among the elderly general population, skeletal fragility—
especially nontrauma fracture (NTFx)—is a primary contrib-
utor to loss of function,7 chronic disease development,8 poor 
quality of life,9 and premature mortality.7,10,11 Moreover, 
health status prior to sustaining a fracture is a strong predic-
tor of postfracture health, function, and survival outcomes.7 
Therefore, adults with epilepsy may have greater risk of post-
NTFx mortality because of their poor skeletal development 
and preservation throughout the lifespan and other unhealth-
ful aging processes. Specifically, individuals with epilepsy 
have greater risk of chronic diseases across biological sys-
tems, including cardiometabolic, respiratory, gastrointestinal, 
liver, and other neurological diseases, as well as a variety of 
mental health disorders.12‒14 Furthermore, there is strong ev-
idence to suggest that individuals with epilepsy have greater 
risk of premature mortality compared to individuals without 
epilepsy.15 However, the contribution of skeletal fragility to 
health and survival outcomes for adults with epilepsy has not 
been investigated.
A better understanding of the link between skeletal fra-
gility and mortality risk is needed for this vulnerable pop-
ulation. If skeletal fragility does increase risk for mortality, 
clinicians caring for patients with epilepsy should be aware 
of the need for strategies to prevent skeletal fragility and in-
tensively manage NTFx and its related sequelae, with the 
ultimate goal of maximizing healthful aging throughout the 
lifespan. Accordingly, the objective of this study was to de-
termine whether NTFx among adults with epilepsy is associ-
ated with greater 12-month mortality rate (MR) compared to 
adults with epilepsy who do not sustain an NTFx and com-
pared to adults without epilepsy who sustain an NTFx. We 
hypothesized that adults with epilepsy who sustain an NTFx 
would have a higher post-NTFx 12-month MR compared 
to both groups, suggesting that (1) NTFx is a risk factor for 
12-month mortality among adults with epilepsy and (2) the 
NTFx-associated 12-month MR is exacerbated for adults 
with versus without epilepsy.
2 |  MATERIALS AND METHODS
2.1 | Data source
Data from 2011 to 2016 were extracted from the Optum 
Clinformatics Data Mart Database (OptumInsight), which 
is an administrative claims database providing information 
from privately insured beneficiaries who had commercial 
or Medicare Advantage plans in the USA.16 These claims-
based data include all health service utilization (eg, inpatient, 
emergency department) for each individual throughout en-
rollment. To maintain patient confidentiality, researchers 
leveraging the Optum database are allowed either the Date 
of Death or Socioeconomic Status table. This study used the 
Date of Death table, and some information regarding socio-
economic status (ie, income, education) was not available. 
Data were deidentified and the university institutional review 
board approved this study as nonregulated.
2.2 | Sample selection
All medical conditions (eg, epilepsy, fracture, comorbidi-
ties) were identified using the International Classification 
of Diseases, Ninth and Tenth Revision (ICD-9 and ICD-
10), Clinical Modification codes to account for the shift in 
K E Y W O R D S
epilepsy, mortality, nontrauma fracture
Key Points
• Adults with epilepsy have increased risk of NTFx 
and premature mortality; however, the link be-
tween the two is unknown
• This private claims–based study from 2011 to 
2016 found that NTFx is a risk factor for mortality 
among adults with epilepsy
• Among adults with epilepsy, NTFx was associated 
with a 187%, 134%, and 70% higher adjusted rate 
of 3-, 6-, and 12-month mortality, respectively
• Among adults who sustained an NTFx, adults with 
versus without epilepsy had an 11%, 29%, and 
41% higher adjusted rate of 3-, 6-, and 12-month 
mortality, respectively
• NTFx across all sites, and especially lower and 
upper extremities, was associated with an elevated 
12-month mortality rate for adults with versus 
without epilepsy
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reporting codes on October 1, 2015, as previously described.17 
Information regarding how diagnoses were made and by 
whom (eg, primary care physician) was not available in ad-
ministrative claims data.
Adults ≥18 years of age with epilepsy were identified 
by at least one inpatient, outpatient, or emergency depart-
ment claim for “epilepsy and recurrent seizures” (ICD-9, 
345 family; ICD-10, G40 family) on at least two different 
days within 365 days of one another. Information regarding 
epilepsy etiology, type, or duration of diagnosis was either 
not available in claims data or not reliably coded (eg, 46% 
had “unspecified” epilepsy), thus not allowing for strati-
fication or statistical adjustment for the clinical subtypes 
of epilepsy. The group of adults without epilepsy included 
individuals with no claims for “epilepsy and recurrent 
seizures.” Using claims to identify epilepsy has high sen-
sitivity and specificity for clinical populations,18 and the 
2+ claim algorithm improves the accuracy of identifying 
“nonevent” medical conditions over a single claim (eg, 
fracture is an “event”).19 For epilepsy, the 2+ algorithm 
has a positive predictive value of ~70%.20
We defined NTFx as a fracture without trauma codes 
(eg, motor vehicle accident) 7 days before to 7 days after 
the index fracture date, as guided by previous studies.17,21,22 
Fractures of the vertebral column, hip (including proximal 
femur), nonproximal femur, tibia/fibula, humerus, ulna/
radius, or unspecified location (ICD-9, 733.1 family, 805-
813 families, 818-823 families, and 827-829 families; 
ICD-10, “initial encounter” codes from S12, S22, S32, 
S42, S52, S72, S82, and M80 families, M84.4, M84.6, and 
M84.7) were identified by at least one inpatient, outpatient, 
or emergency department claim from 2012 to 2015. This 
time frame was selected to allow for at least 1 full year of a 
“look back” period for those experiencing fracture in 2012 
to ascertain baseline comorbidity data and at least 1 full 
year of follow-up for those experiencing fracture in 2015 
for the outcome. Using a single claim to capture fracture 
has excellent accuracy, with up to 98% positive predictive 
value, which is similar to or better than other algorithms 
(eg, 2+ claims).23
The sample was then categorized based on epilepsy and 
NTFx status: (1) with epilepsy and NTFx (EP + NTFx), with 
epilepsy and without NTFx (EP without NTFx), without ep-
ilepsy and with NTFx (without EP  +  NTFx), and without 
epilepsy and without NTFx (without EP without NTFx). The 
start date of the follow-up was the index date of NTFx or 
a randomly assigned date for those who did not sustain an 
NTFx. For the latter, we used a uniform distribution (visu-
ally inspected by S.B.) to randomly assign a date during the 
individual's enrollment period between January 1, 2012 and 
December 31, 2015.
We included individuals who had at least 12 full months 
of continuous enrollment in a health plan prior to their start 
date of follow-up to sequester baseline comorbidity data, as 
previously described.19
2.3 | Outcome measure
All-cause mortality from 2012 to 2016 was determined as 
the number of days from the start date of follow-up to date of 
death, and separated as 3-, 6-, and 12-month time points (6 
and 12 months were cumulative).
2.4 | Covariates
Covariates were selected based on their relevance to adults 
with epilepsy, NTFx, and mortality, as well as availability 
in the administrative claims databases. Sociodemographic 
variables included age, sex, race, and US region of residence 
(West, Midwest, South, and Northeast). Baseline comorbidi-
ties were identified from 2011 to 2015 by at least (1) one in-
patient claim within the 12 months prior to the start date of 
follow-up; or (2) two outpatient claims on different claim days 
within 365 days of one another, with the first outpatient claim 
occurring within the 12 months prior to the start date of fol-
low-up.19 Comorbidities included cardiovascular disease (ie, 
ischemic heart disease, heart failure, cerebrovascular disease), 
hypertension, diabetes (ie, type 1, type 2), respiratory disease 
(ie, acute respiratory infection, pneumonia, chronic obstruc-
tive pulmonary disease, interstitial/pleura disease, other res-
piratory disease), chronic kidney disease (stages I-V), and 
cancer anywhere in the body, as previously described.17,24
2.5 | Statistical analysis
Descriptive characteristics at baseline were summarized for 
each group. MRs were estimated as the number of deaths 
divided by the number of person-years, and expressed per 
100 person-years for each group. MR ratios (MRRs) and 
95% confidence intervals (CIs) were estimated comparing 
the groups to one another.
Cox regression was used to adjust for all covariates when 
comparing MR, by estimating hazard ratios (HRs) and 95% 
CIs of mortality at all time points, comparing the groups 
to one another. The primary group comparisons of interest 
were: (1) EP + NTFx versus EP without NTFx to determine 
whether NTFx is a risk factor for mortality among adults with 
epilepsy and (2) EP + NTFx versus without EP + NTFx to 
determine whether NTFx exacerbates MR for adults with 
versus without epilepsy. Possible interactions between expo-
sure status and age or sex were assessed by conducting sepa-
rate analyses for age or sex strata (to estimate group effects) 
and by including product terms in the Cox models (to test for 
   | 717WHITNEY ET al
interactions). Individuals were right censored if they discon-
tinued health plan enrollment or were alive at the end of the 
study period.
We then examined crude MR and MRR and adjusted HR 
of 12-month mortality by NTFx location to identify site-spe-
cific effects using the procedures described above.
2.6 | Sensitivity analysis
Cox regression did not adjust for race to limit bias due to 
missing data (~14%). We therefore conducted two related 
sensitivity analyses to assess possible confounding and selec-
tion bias. Sensitivity analysis #1 involved the restricted study 
population with complete data on race but not adjusting for 
race; sensitivity analysis #2 involved the same study popula-
tion as in #1 but adjusted for race. Results were compared 
from sensitivity analyses #1 and #2 to assess possible con-
founding by race. Results were also compared from sensitiv-
ity analysis #1 (restricted study population not adjusting for 
race) and the main analysis (full study population not adjust-
ing for race) to assess possible selection bias from exclusion 
of adults without race data.
Analyses were performed using SAS version 9.4 (SAS 
Institute).
3 |  RESULTS
Baseline descriptive characteristics of EP  +  NTFx 
(n  =  11  471), EP without NTFx (n  =  50  384), without 
EP + NTFx (n = 423 041), and without EP without NTFx 
(n = 6 787 743) is presented in Table 1. Notably, the two 
NTFx groups were older and had a higher proportion of 
women than the two non-NTFx groups.
3.1 | Crude MR
The crude MRs and MRRs are presented in Table 2. The 
crude MRs for all time points were highest for EP + NTFx 
(eg, 12-month MR = 8.79 per 100 person-years), followed by 
without EP + NTFx (eg, 12-month MR = 4.80), EP without 
NTFx (eg, 12-month MR = 3.06), and without EP without 
NTFx (eg, 12-month MR = 0.47). The MR remained rela-
tively stable for the two non-NTFx groups from 3 months to 
12 months, but declined in the two NTFx groups. The crude 
MRR was elevated for EP  +  NTFx compared to EP with-
out NTFx and without EP + NTFx for all time points. When 
without EP without NTFx was the reference, the crude MRR 
was elevated for all groups for all time points, with a larger 
decline in MRR for the two NTFx groups compared to the EP 
without NTFx group.
3.2 | Cox regression analysis of mortality
Adjusted mortality HRs are presented in Table 3. Compared 
to without EP without NTFx, the HR adjusting for all co-
variates was highest for EP + NTFx across all time points 
(eg, 12-month HR  =  5.23, 95% CI  =  4.88-5.60), followed 
by without EP  +  NTFx (eg, 12-month HR  =  3.71, 95% 
CI  =  3.64-3.78) and EP without NTFx (eg, 12-month 
HR = 3.08, 95% CI = 2.92-3.25). The adjusted HR compar-
ing EP  +  NTFx to EP without NTFx was elevated for all 
time points, with the group effect becoming smaller from 
3 months (HR  =  2.87, 95% CI  = 2.47-3.33) to 12 months 
(HR = 1.70, 95% CI = 1.58-1.85). The adjusted HR com-
paring EP + NTFx to without EP + NTFx was elevated for 
all time points, with the group effect becoming larger from 
3  months (HR  =  1.11, 95% CI  = 1.00-1.23) to 12 months 
(HR = 1.41, 95% CI = 1.32-1.51).
3.3 | Site-specific effect of NTFx on 
12-month MR
Table 4 shows the MR, MRR, and adjusted HR for 12-
month mortality stratified by NTFx location. The site-
specific patterns of MR were consistent for the two NTFx 
groups; hip had the highest MR, followed by vertebral col-
umn and extremities. The crude MR and MRR were el-
evated for adults with versus without epilepsy for all sites. 
After adjusting for all covariates, the HR for adults with 
versus without epilepsy was elevated for all sites, with the 
lower extremities (HR  =  1.92, 95% CI  =  1.61-2.30) and 
upper extremities (HR = 1.79, 95% CI = 1.51-2.12) having 
the highest HR.
3.4 | Interactions of group with age and sex
Table 5 (age) and Table 6 (sex) show the MR, MRR, and 
adjusted HR of mortality by age category (18-40, 41-64, 
and ≥65  years) and sex (both P for interaction  <  .001). 
There were too few deaths in the EP without NTFx and 
EP  +  NTFx groups for the 18-40  year age category for 
analyses (n ≤ 40). EP + NTFx had an elevated MR, MRR, 
and adjusted HR compared to EP without NTFx and with-
out EP + NTFx for the 41-64 year and ≥65 year age groups 
and for both women and men. The ≥65 year age group for 
all groups by epilepsy and NTFx status had higher MR 
than the 18-40 and 41-64  year age groups. The absolute 
difference in MR for EP + NTFx versus EP without NTFx 
and without EP + NTFx was larger in the ≥65 year ver-
sus younger age groups, but the relative MRR was larger 
for EP  +  NTFx versus EP without NTFx and without 
EP + NTFx in the 41-64 year versus ≥65 year age group. 
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Men had a higher MR for all groups compared to women. 
The absolute difference in MR was larger for men than 
women for EP + NTFx versus EP without NTFx and with-
out EP + NTFx, and the relative MRR was larger for men 
than women for EP + NTFx versus EP without NTFx.
3.5 | Sensitivity analysis
There were 6 257 223 individuals with complete data on 
race. The adjusted HR was higher for EP + NTFx versus 














Age, mean (SD) 67.1 (15.9) 57.6 (18.6) 65.0 (18.5) 51.7 (18.5)
18-40 y, % 7.1 20.3 12.7 30.5
41-64 y, % 31.1 38.9 28.4 41.1
≥65 y, % 61.8 40.8 58.9 28.5
Sex, %
Women 62.4 53.4 66.2 51.4
Men 37.6 46.6 33.8 48.6
Race, %
White 66.2 63.9 68.9 63.7
Black 9.4 11.1 6.5 8.4
Hispanic 7.3 8.6 7.9 9.7
Asian 1.7 2.2 2.5 4.2
Unknown/missing 15.4 14.2 14.2 14.0
US region, %
West 26.1 23.2 28.2 24.1
Midwest 22.3 23.4 24.5 25.2
South 38.9 41.1 36.2 40.5
Northeast 12.7 12.3 11.2 10.3
Comorbidities, %
Cardiovascular diseasea 43.4 28.7 21.7 7.8
Hypertension 65.4 49.0 51.7 27.5
Diabetes 25.6 20.4 19.9 11.5
Respiratory diseaseb 41.9 30.3 27.4 14.8
Chronic kidney disease 15.0 9.4 10.5 3.5
Cancer 24.1 19.2 19.2 11.2
Fracture distributionc
Unspecified location 2.1   4.5  
Vertebral column 30.1   25.4  
Hip 22.7   16.7  
Femur, nonproximal 3.6   3.1  
Tibia/fibula 18.0   22.9  
Humerus 12.5   9.8  
Ulna/radius 12.8   19.2  
Abbreviations: EP, epilepsy; NTFx, nontrauma fracture.
aIschemic heart disease, heart failure, and/or cerebrovascular disease. 
bAcute respiratory infection, pneumonia, chronic obstructive pulmonary disease, interstitial/pleura disease, 
and/or other respiratory disease (eg, respiratory failure). 
cSome individuals had an NTFx across multiple sites. 
T A B L E  1  Baseline descriptive 
characteristics by status of EP and NTFx
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covariate  +  race HR rounded to the same values; both 
HR = 2.98, 95% CI = 2.54-3.50), 6 months (covariate ad-
justed HR = 2.33, 95% CI = 2.07-2.62; covariate +  race 
HR = 2.34, 95% CI = 2.08-2.63), and 12 months (covariate 
adjusted HR = 1.71, 95% CI = 1.56-1.88; covariate + race 
HR = 1.72, 95% CI = 1.57-1.88). The adjusted HR was higher 
for EP + NTFx versus without EP + NTFx for 3 months 
(covariate adjusted HR  =  1.13, 95% CI  =  1.01-1.27; 
covariate + race HR = 1.12, 95% CI = 1.00-1.25), 6 months 
(covariate adjusted HR = 1.31, 95% CI = 1.20-1.43; covari-
ate + race HR = 1.29, 95% CI = 1.18-1.41), and 12 months 
(covariate adjusted HR  =  1.43, 95% CI  =  1.33-1.54; co-
variate + race HR = 1.41, 95% CI = 1.31-1.52). A com-
parison of the HR estimates from sensitivity analyses #1 
and #2 yielded similar results, suggesting that race is not 
a confounder in the main analysis. A comparison of HR 
T A B L E  2  Crude mortality rate and 
RR by status of EP and NTFxMortality cases 3-mo mortality, n 6-mo mortality, n
12-mo 
mortality, n
Without EP without NTFx 7150 14 297 28 505
Without EP + NTFx 9003 12 656 17 397
EP without NTFx 324 668 1399
EP + NTFx 354 579 856
Crude mortality rate
Per 100  
person-years, n
Per 100  
person-years, n
Per 100  
person-years, n
Without EP without NTFx 0.43 0.45 0.47
Without EP + NTFx 8.90 6.51 4.80
EP without NTFx 2.63 2.77 3.06
EP + NTFx 12.89 11.01 8.79
Crude mortality RR RR (95% CI) RR (95% CI) RR (95% CI)
Reference: without EP without NTFx
Without EP + NTFx 20.54 (19.91-21.19) 14.62 (14.27-14.97) 10.23 (10.03-10.41)
EP without NTFx 6.07 (5.43-6.78) 6.22 (5.76-6.73) 6.51 (6.17-6.87)
EP + NTFx 29.75 (26.74-33.10) 24.71 (22.74-26.85) 18.72 (17.49-20.03)
Reference: without EP + NTFx
EP without NTFx 0.30 (0.26-0.33) 0.43 (0.39-0.46) 0.64 (0.60-0.67)
EP + NTFx 1.45 (1.30-1.61) 1.69 (1.56-1.84) 1.83 (1.71-1.96)
Reference: EP without NTFx
EP + NTFx 4.91 (4.22-5.70) 3.97 (3.55-4.44) 2.88 (2.64-3.13)
Abbreviations: CI, confidence interval; EP, epilepsy; NTFx, nontrauma fracture; RR, rate ratio.
T A B L E  3  Adjusted HR of mortality 







Reference: without EP without NTFx
Without EP + NTFx 7.19 (6.96-7.43) 5.20 (5.07-5.33) 3.71 (3.64-3.78)
EP without NTFx 2.78 (2.48-3.11) 2.88 (2.66-3.11) 3.08 (2.92-3.25)
EP + NTFx 7.96 (7.15-8.87) 6.73 (6.19-7.32) 5.23 (4.88-5.60)
Reference: without EP + NTFx
EP without NTFx 0.39 (0.35-0.43) 0.55 (0.51-0.60) 0.83 (0.79-0.88)
EP + NTFx 1.11 (1.00-1.23) 1.29 (1.19-1.41) 1.41 (1.32-1.51)
Reference: EP without NTFx
EP + NTFx 2.87 (2.47-3.33) 2.34 (2.09-2.61) 1.70 (1.58-1.85)
Note: Adjusted for age, sex, US region, cardiovascular disease, respiratory disease, diabetes, chronic kidney 
disease, cancer, and hypertension.
Abbreviations: CI, confidence interval; EP, epilepsy; HR, hazard ratio; NTFx, nontrauma fracture.
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estimates from sensitivity analysis #1 with results from the 
main analysis show similar results, suggesting no evidence 
of selection bias.
4 |  DISCUSSION
Findings from this study suggest that the elevated mortality 
burden for adults with epilepsy15 may be exacerbated by skel-
etal fragility. One main finding of this investigation is that 
NTFx was associated with mortality within 12 months among 
adults with epilepsy, suggesting that NTFx is a risk factor for 
mortality for this population. The other main finding of this 
investigation was that among those who sustained an NTFx, 
adults with epilepsy had higher rates of mortality within 
12 months compared to adults without epilepsy, suggesting 
a greater NTFx-attributable mortality burden for adults with 
epilepsy. These findings were evident across NTFx sites and 
after accounting for covariates that are associated with pre-
mature mortality. Taken together, study findings suggest that 
NTFx, an indicator of skeletal fragility, may be implicated in 
the pathogenesis of unhealthful aging for adults with epilepsy.
A recent systematic review including 46 studies con-
cluded that individuals with epilepsy are at risk for premature 
mortality.15 Although the burden of premature mortality var-
ied among epilepsy-related factors (eg, etiology), the stan-
dardized mortality ratios were still elevated for most studies 
regardless of age, sex, etiology, type, and time since diagno-
sis. In the elderly general population, fracture is associated 
with mortality7,10,11 and chronic diseases,8,25 and postfracture 
chronic disease development may be involved in the frac-
ture-mortality association.8,25,26 The most common causes 
of death for individuals with epilepsy include chronic dis-
eases (eg, cardiovascular and respiratory disease), injuries 
(eg, seizures, falls), and cancer.15,27‒29 Therefore, the current 
study provides new potential insights into factors that may be 
involved directly with mortality or indirectly with mortality 
via early pathological processes for adults with epilepsy, as 
NTFx is an adverse outcome of injuries (eg, seizures, falls) 
and increases risk of chronic diseases.
In the current study, the crude analysis found that MR was 
highest among EP + NTFx, followed by without EP + NTFx, 
EP without NTFx, and without EP without NTFx. 
Interestingly, the non-NTFx groups had a relatively consis-
tent MR across the 3-, 6-, and 12-month time points, whereas 
the two NTFx groups had the highest MR at 3 months and 
a gradual decline to 12 months. Even with this decline, the 
MR was higher for all time points compared to the non-NTFx 
groups. This finding is consistent with the conviction that 
there may be a unique set of factors associated with short- 
and long-term mortality post-NTFx.30 However, the mech-
anisms explaining the NTFx-induced mortality have yet to 
be elucidated and may be further confounded by the medical 
complexities of epilepsy (eg, antiseizure medications).
We used Cox regression to adjust for demographics and sev-
eral chronic diseases that are associated with NTFx and mortal-
ity to better understand the link between epilepsy, NTFx, and 
mortality beyond these covariates. In our primary comparisons 
of interest, we found that the adjusted rate of 3-, 6-, and 12-month 
mortality was higher for EP + NTFx compared to EP without 
T A B L E  4  Twelve-month mortality 









Without EP + NTFx 6391 6420 1951 2514











Without EP + NTFx 7.01 11.22 2.06 2.35
EP + NTFx 9.93 13.34 6.00 5.76
Crude mortality RR RR (95% CI) RR (95% CI) RR (95% CI) RR (95% CI)
Reference: without EP + NTFx
EP + NTFx 1.42 (1.26-1.59) 1.19 (1.06-1.34) 2.92 (2.44-3.49) 2.45 (2.07-2.90)
Adjusted HR HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
Reference: without EP + NTFx
EP + NTFx 1.30 (1.16-1.47) 1.15 (1.02-1.30) 1.92 (1.61-2.30) 1.79 (1.51-2.12)
Note: Adjusted for age, sex, US region, cardiovascular disease, respiratory disease, diabetes, chronic kidney 
disease, cancer, and hypertension.
Abbreviations: CI, confidence interval; EP, epilepsy; HR, hazard ratio; NTFx, nontrauma fracture; RR, rate 
ratio.
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NTFx and without EP + NTFx. Specifically, EP + NTFx had 
a 2.9-fold higher rate of mortality in the 3  months following 
the NTFx event compared to EP without NTFx. The adjusted 
risk declined over the time points, but still remained elevated, 
with a 70% higher adjusted rate of mortality at 12 months. The 
adjusted rate of mortality for EP + NTFx compared to without 
EP + NTFx increased over the time points, from 11% higher rate 
at 3 months to 41% higher rate at 12 months.
When we stratified NTFx by location, we found that all sites 
were associated with higher adjusted 12-month MR among 
adults with versus without epilepsy. However, we found that 
NTFx of the lower and upper extremities was associated with 
higher relative MRs compared to the hip and vertebral column 
(92%, 79%, 15%, and 30%, respectively). However, it is import-
ant to note that the absolute MR was still much higher for NTFx 
of the hip and vertebral column than extremities for adults with 
and without epilepsy. Therefore, NTFx at all of these sites 
should be treated with urgency (eg, aggressive monitoring and 
treatment interventions) for adults with epilepsy, and especially 
if NTFx occurs in the lower or upper extremities.
Finally, we found that the excess mortality burden at-
tributable to NTFx for adults with epilepsy from the whole 
T A B L E  5  Twelve-month mortality 
rate, RR, and adjusted HR by status of EP 
and NTFx by age categories
Mortality cases 18-40 y, n 41-64 y, n ≥65 y, n
without EP without NTFx 312 3612 24 581
without EP + NTFx 64 1325 16 008
EP without NTFx 40 292 1067








without EP without NTFx 0.02 0.15 1.38
without EP + NTFx 0.14 1.28 7.50
EP without NTFx 0.44 1.64 5.70
EP + NTFx 1.14 4.81 11.80
Crude mortality RR RR (95% CI) RR (95% CI) RR (95% CI)
Reference: without EP without NTFx
Without EP + NTFx 8.09 (6.18-10.58) 8.81 (8.27-9.38) 5.46 (5.35-5.57)
EP without NTFx a 11.24 (9.98-12.66) 4.15 (3.90-4.41)
EP + NTFx a 33.04 (28.05-38.92) 8.58 (7.96-9.25)
Reference: without EP + NTFx
EP without NTFx a 1.28 (1.12-1.45) 0.76 (0.72-0.81)
EP + NTFx a 3.75 (3.17-4.45) 1.57 (1.46-1.70)
Reference: EP without NTFx
EP + NTFx a 2.94 (2.41-3.58) 2.07 (1.88-2.28)
Adjusted HR HR (95% CI) HR (95% CI) HR (95% CI)
Reference: without EP without NTFx
Without EP + NTFx 6.32 (4.81-8.31) 5.21 (4.88-5.57) 3.48 (3.41-3.55)
EP without NTFx a 4.43 (3.92-5.01) 2.65 (2.49-2.82)
EP + NTFx a 8.78 (7.43-10.38) 4.54 (4.21-4.90)
Reference: without EP + NTFx
EP without NTFx a 0.85 (0.75-0.97) 0.76 (0.72-0.81)
EP + NTFx a 1.68 (1.42-2.00) 1.30 (1.21-1.41)
Reference: EP without NTFx
EP + NTFx a 1.98 (1.63-2.41) 1.71 (1.56-1.88)
Note: Adjusted for age, sex, US region, cardiovascular disease, respiratory disease, diabetes, chronic kidney 
disease, cancer, and hypertension.
Abbreviations: CI, confidence interval; EP, epilepsy; HR, hazard ratio; NTFx, nontrauma fracture; RR, rate 
ratio.
aSample size was insufficient for analysis. 
722 |   WHITNEY ET al
sample was consistent across the age spectrum (ie, young, 
middle-aged, and older) and for women and men. However, 
we found that the group effect estimate was larger for mid-
dle-age than older age for EP + NTFx versus EP without 
NTFx and without EP + NTFx, and for men than women 
for EP + NTFx versus EP without NTFx. Taken together, 
these findings suggest that the NTFx-attributable mortal-
ity burden is more problematic for individuals with ver-
sus without epilepsy across the adult lifespan and for both 
women and men, but that younger age subjects and men 
with epilepsy may have a higher relative vulnerability to 
the NTFx-mortality burden.
Prefracture diseases,31 functional capacity,32 and physical 
ability (eg, muscle strength)33 are risk factors for postfracture 
premature mortality, and a follow-up fracture further exac-
erbates mortality risk.33 The systemic stress induced by an 
NTFx may create an unfavorable physiological environment 
that exacerbates risk for post-NTFx complications and prema-
ture mortality, through either direct or indirect mechanisms.30 
Individuals with epilepsy are particularly susceptible to post-
NTFx complications because of their greater lifetime burden 
of unhealthful aging, as evidenced by an elevated prevalence 
of chronic diseases in adulthood.12‒14 Therefore, adults with 
epilepsy may already have a compromised physiological en-
vironment and skeletal fragility (eg, history of NTFx), and 
sustaining an NTFx may further exacerbate risk of post-
NTFx complications and premature mortality. Future stud-
ies are needed to disentangle the complex factors involved in 
T A B L E  6  Twelve-month mortality 
rate, RR, and adjusted HR by status of EP 
and NTFx by sex
Mortality cases Women, n Men, n
Without EP without NTFx 13 773 14 732
Without EP + NTFx 10 343 7054
EP without NTFx 682 717
EP + NTFx 464 392
Crude mortality rate Per 100 person-years, n Per 100 person-years, n
Without EP without NTFx 0.44 0.50
Without EP + NTFx 4.27 5.87
EP without NTFx 2.80 3.36
EP + NTFx 7.52 10.99
Crude mortality RR RR (95% CI) RR (95% CI)
Reference: without EP without NTFx
Without EP + NTFx 9.66 (9.42-9.91) 11.76 (11.43-12.10)
EP without NTFx 6.33 (5.86-6.84) 6.72 (6.23-7.24)
EP + NTFx 17.03 (15.53-18.68) 22.00 (19.90-24.32)
Reference: without EP + NTFx
EP without NTFx 0.66 (0.61-0.71) 0.57 (0.53-0.62)
EP + NTFx 1.76 (1.61-1.94) 1.87 (1.69-2.07)
Reference: EP without NTFx
EP + NTFx 2.69 (2.39-3.03) 3.28 (2.90-3.70)
Adjusted HR HR (95% CI) HR (95% CI)
Reference: without EP without NTFx
Without EP + NTFx 3.20 (3.12-3.29) 4.43 (4.30-4.57)
EP without NTFx 3.05 (2.82-3.29) 3.11 (2.88-3.35)
EP + NTFx 4.35 (3.97-4.78) 6.39 (5.78-7.07)
Reference: without EP + NTFx
EP without NTFx 0.95 (0.88-1.03) 0.70 (0.65-0.76)
EP + NTFx 1.36 (1.24-1.49) 1.44 (1.30-1.60)
Reference: EP without NTFx
EP + NTFx 1.43 (1.27-1.61) 2.06 (1.82-2.33)
Note: Adjusted for age, US region, cardiovascular disease, respiratory disease, diabetes, chronic kidney 
disease, cancer, and hypertension.
Abbreviations: CI, confidence interval; EP, epilepsy; HR, hazard ratio; NTFx, nontrauma fracture; RR, rate ratio.
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post-NTFx mortality unique to individuals with epilepsy, and 
to determine to what extent the NTFx-mortality association 
is mediated by preventable (eg, serious falls, postoperative 
complications), modifiable (eg, physical activity), or treat-
able (eg, chronic disease) factors.
The limitations of this study must be discussed. First, 
there is a risk of biasing effect estimates from unmeasured 
confounding due to the limited set of comorbidities, the ob-
servational design, and the lack of medication information, 
as we were not able to ascertain pharmacy claims. In light 
of these factors, we computed E values34,35 to determine 
the extent of unmeasured confounding (minimum strength 
of association with the exposure and outcome) needed to 
fully explain away a specific exposure-outcome association, 
conditional on the set of covariates. We used the fully ad-
justed Cox regression model for each analysis. The E value 
(lower 95% CI) needed to fully explain away the effect for 
EP  +  NTFx versus EP without NTFx was 5.19 (4.38) for 
3 months, 4.11 (3.60) for 6 months, and 2.79 (2.54) for 12 
months. The E value (lower 95% CI) needed to fully explain 
away the effect for EP + NTFx versus without EP + NTFX 
was 1.46 (1.00) for 3 months, 1.90 (1.67) for 6 months, and 
2.17 (1.97) for 12 months. Given the careful selection of co-
variates in the design of the Cox regression models as well as 
the large E values, it appears unlikely that unmeasured con-
founding (eg, lack of medication information) largely biased 
effect estimates for the exposure variables. Second, we were 
unable to account for the type, etiology, or time since diag-
nosis of epilepsy, which may have provided deeper insight 
into the NTFx-mortality burden. Third, it is not possible to 
reliably determine the cause of fracture using claims data. 
Approximately one-third of fractures can be attributable to 
seizures for adults with epilepsy.36 Seizures by themselves 
may not be considered traumatic and would therefore not be 
given a trauma code in the claims database (eg, not including 
seizures that lead to a motor vehicle accident). A fracture not 
having a trauma code around the date of fracture would be 
considered an NTFx in the current study. Fourth, epilepsy 
was not determined using diagnosis codes for a single seizure 
(ICD-10, G41 family codes) or convulsions (ICD-9, 780.3x; 
ICD-10, R56.8), in part due to a potential for misclassifica-
tion of epilepsy; however, misclassification for this reason 
would have a negligible impact on study findings given the 
large sample size.
In conclusion, study findings suggest that NTFx is a risk 
factor for mortality among adults with epilepsy, and com-
pared to adults without epilepsy, NTFx elicits a higher MR 
for up to 12 months for adults with epilepsy. Furthermore, 
while NTFx across all sites is associated with an elevated 12-
month MR for adults with versus without epilepsy, there may 
be a stronger mortality association with NTFx of the lower 
and upper extremities. Future clinical research is needed 
to identify strategies to prevent and better manage skeletal 
fragility with the aim of reducing the burden of skeletal fra-
gility and improving healthful aging for adults with epilepsy. 
Future basic and translational studies are needed that exam-
ine mechanisms linking skeletal fragility with mortality spe-
cific to the population of adults with epilepsy.
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